Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other financing activities (2020 - 2025)

Historic Other financing activities for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $4881.0.

  • SAB Biotherapeutics' Other financing activities changed N/A to $4881.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $29795.0, marking a year-over-year change of. This contributed to the annual value of $24931.0 for FY2024, which is 16018.58% up from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Other financing activities is $4881.0.
  • SAB Biotherapeutics' Other financing activities' 5-year high stood at $349115.0 during Q1 2021, with a 5-year trough of -$201477.0 in Q4 2021.
  • In the last 5 years, SAB Biotherapeutics' Other financing activities had a median value of $3655.5 in 2023 and averaged $11540.6.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 35143.14% in 2021, then soared by 98000.0% in 2024.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Other financing activities stood at -$201477.0 in 2021, then skyrocketed by 134.32% to $69141.0 in 2022, then tumbled by 96.49% to $2430.0 in 2023, then surged by 740.0% to $20412.0 in 2024, then crashed by 76.09% to $4881.0 in 2025.
  • Its Other financing activities was $4881.0 in Q3 2025, compared to $2072.0 in Q1 2025 and $20412.0 in Q1 2024.